The application of artificial intelligence to drug sensitivity prediction
Xutong Li,Xiaolong Wu,Xiaolong Wu,Xiaozhe Wan,Feisheng Zhong,Chen Cui,Yingjia Chen,Lifan Chen,Kaixian Chen,Hualiang Jiang,Mingyue Zheng +10 more
Reads0
Chats0
TLDR
In this article, the authors summarize the characteristics of publicly accessible genomic databases and discuss the trends of artificial intelligence applications in drug sensitivity prediction for cancer cell lines, including machine learning, networks and multimodal deep neural networks.Abstract:
The development of computational methods for the prediction of effective therapeutic strategies based on the genomic information of patients is the main challenge of precision medicine. Since the 21st century, next-generation sequencing (NGS) has opened up new possibilities for personalized medicine. Extensive characterization at the molecular level for hundreds of cancer cell lines has been brought to the public eye by many organizations and agencies around the world. For example, the National Cancer Institute 60 Human Cancer Cell Line Screen (NCI-60), Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (GDSC) have provided large-scale omics data such as genomic, transcriptomic and epigenomic data characterizing cancer cell lines, and The Cancer Genome Atlas (TCGA) has molecularly characterized over 20000 primary cancers of patients. Combined with the drug response data of cancer cell lines, multiomics data could be used to analyse the mechanisms of action of anticancer drugs, which could be incorporated into precision medicine strategies. Over several decades, artificial intelligence (AI) technologies based on big data have revolutionized bioinformatics. AI has built a bridge between genomics and drug sensitivity by promoting the development of predictive models for the drug response of cancer cell lines. The 2012 NCI-DREAM drug prediction challenge has been particularly influential, as the innovative applications of machine learning that emerged from it have laid the groundwork for future studies. However, classic machine learning models are still challenging in terms of predictability because they limit the systematic integration of high-dimensional multiomics data. Therefore, network-based approaches, including link prediction and network representation, have become mainstream methods for drug response prediction. On the one hand, network-based approaches have not faced the “small n, large p” problem since the multiomics features are either represented in a gene/protein network or embedded in similarity networks between cell lines. On the other hand, the introduction of gene regulatory networks (GRNs) and protein-protein interactions (PPIs) into the predictive model can provide a functional background for the integration of genomic data and thereby improve the predictive performance of drug response. In addition to network-based approaches, multimodal deep learning models can systematically integrate multiomic data by considering them as different modalities. Generally, there are three feature fusion methods in deep neural networks: Input-level feature fusion (early fusion), intermediate feature fusion and decision-level fusion (late fusion). Intermediate feature fusion is predominant in drug response prediction studies, by which features are learned separately for each type of omics data and then integrated into one unified representation to be used as the input for a classifier or a regressor. Moreover, the features of drug structures can be used as a model to improve the performance. In brief, we summarize the characteristics of publicly accessible genomic databases and discuss the trends of artificial intelligence applications in drug sensitivity prediction for cancer cell lines, including machine learning, networks and multimodal deep neural networks.read more
Citations
More filters
Book ChapterDOI
Artificial Intelligence Technology in Enterprise Economic Management.
TL;DR: This research mainly discusses the research and application of artificial intelligence technology in enterprise economic management, using AI technology, dynamically collecting and analyzing data, timely warning, and timely stop loss in the project approval stage.
References
More filters
Proceedings ArticleDOI
FaceNet: A unified embedding for face recognition and clustering
TL;DR: A system that directly learns a mapping from face images to a compact Euclidean space where distances directly correspond to a measure offace similarity, and achieves state-of-the-art face recognition performance using only 128-bytes perface.
Journal ArticleDOI
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina,Giordano Caponigro,Nicolas Stransky,Kavitha Venkatesan,Adam A. Margolin,Adam A. Margolin,Sungjoon Kim,Christine D. Wilson,Joseph Lehar,Gregory V. Kryukov,Dmitriy Sonkin,Anupama Reddy,Manway Liu,Lauren Murray,Michael F. Berger,Michael F. Berger,John Monahan,Paula Morais,Jodi Meltzer,Adam Korejwa,Judit Jané-Valbuena,Judit Jané-Valbuena,Felipa A. Mapa,Joseph Thibault,Eva Bric-Furlong,Pichai Raman,Aaron Shipway,Ingo H. Engels,Jill Cheng,Guoying K. Yu,Jianjun Yu,Peter Aspesi,Melanie de Silva,Kalpana Jagtap,Michael D. Jones,Li Wang,Charlie Hatton,Emanuele Palescandolo,Supriya Gupta,Scott Mahan,Carrie Sougnez,Robert C. Onofrio,Ted Liefeld,Laura E. MacConaill,Wendy Winckler,Michael R. Reich,Nanxin Li,Jill P. Mesirov,Stacey Gabriel,Gad Getz,Kristin G. Ardlie,Vivien W. Chan,Vic E. Myer,Barbara L. Weber,Jeffrey A. Porter,Markus Warmuth,Peter Finan,Jennifer L. Harris,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Michael Morrissey,William R. Sellers,Robert Schlegel,Levi A. Garraway,Levi A. Garraway +65 more
TL;DR: The results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents and the generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of ‘personalized’ therapeutic regimens.
Journal Article
The Cancer Genome Atlas Pan-Cancer analysis project
Kyle Chang,Chad J Creighton,Caleb F. Davis,Lawrence A. Donehower,Jennifer Drummond,David A. Wheeler,Adrian Ally,Miruna Balasundaram,Inanc Birol,Yaron S.N. Butterfield,Andy Chu,Eric Chuah,Hye Jung E. Chun,Noreen Dhalla,Ranabir Guin,Martin Hirst,Carrie Hirst,Robert A. Holt,Steven J.M. Jones,Darlene Lee,Haiyan I. Li,Marco A. Marra,Michael Mayo,Richard A. Moore,Andrew J. Mungall,A. Gordon Robertson,Jacqueline E. Schein,Payal Sipahimalani,Angela Tam,Nina Thiessen,Richard Varhol,Rameen Beroukhim,Ami S. Bhatt,Angela N. Brooks,Andrew D. Cherniack,Samuel S. Freeman,Stacey Gabriel,Elena Helman,Joonil Jung,Matthew Meyerson,Akinyemi I. Ojesina,Chandra Sekhar Pedamallu,Gordon Saksena,Steven E. Schumacher,Barbara Tabak,Travis I. Zack,Eric S. Lander,Christopher A. Bristow,Angela Hadjipanayis,Psalm Haseley,Raju Kucherlapati,Semin Lee,Eunjung Lee,Lovelace J. Luquette,Harshad S. Mahadeshwar,Angeliki Pantazi,Michael Parfenov,Peter J. Park,Alexei Protopopov,Xiaojia Ren,Netty Santoso,Jonathan G. Seidman,Sahil Seth,Xingzhi Song,Jiabin Tang,Ruibin Xi,Andrew Wei Xu,Lixing Yang,Dong Zeng,J. Todd Auman,Saianand Balu,Elizabeth Buda,Cheng Fan,Katherine A. Hoadley,Corbin D. Jones,Shaowu Meng,Piotr A. Mieczkowski,Joel S. Parker,Charles M. Perou,Jeffrey Roach,Yan Shi,Grace O. Silva,Donghui Tan,Umadevi Veluvolu,Scot Waring,Matthew D. Wilkerson,Junyuan Wu,Wei Zhao,Tom Bodenheimer,D. Neil Hayes,Alan P. Hoyle,Stuart R. Jeffreys,Lisle E. Mose,Janae V. Simons,Mathew G. Soloway,Stephen B. Baylin,Benjamin P. Berman,Moiz S. Bootwalla,Ludmila Danilova,James G. Herman,Toshinori Hinoue,Peter W. Laird,Suhn K. Rhie,Hui Shen,Timothy J. Triche,Daniel J. Weisenberger,Scott L. Carter,Kristian Cibulskis,Lynda Chin,Jianhua Zhang,Gad Getz,Carrie Sougnez,Min Wang,Huyen Dinh,Harshavardhan Doddapaneni,Richard A. Gibbs,Preethi H. Gunaratne,Yi Han,Divya Kalra,Christie Kovar,Lora Lewis,Margaret Morgan,Donna Morton,Donna M. Muzny,Jeffrey G. Reid,Liu Xi,Juok Cho,Daniel DiCara,Scott Frazer,Nils Gehlenborg,David I. Heiman,Jaegil Kim,Michael S. Lawrence,Pei Lin,Yingchun Liu,Michael S. Noble,Petar Stojanov,Doug Voet,Hailei Zhang,Lihua Zou,Chip Stewart,Brady Bernard,Ryan Bressler,Andrea Eakin,Lisa Iype,Theo A. Knijnenburg,Roger Kramer,Richard Kreisberg,Kalle Leinonen,Jake Lin,Yuexin Liu,Michael W. Miller,Sheila Reynolds,Hector Rovira,Ilya Shmulevich,Vesteinn Thorsson,Da Yang,Wei Zhang,Samirkumar B. Amin,Chang-Jiun Wu,Chia Chin Wu,Rehan Akbani,Kenneth Aldape,Keith A. Baggerly,Bradley M. Broom,Tod D. Casasent,James Cleland,Chad J. Creighton,Deepti Dodda,Mary E. Edgerton,Leng Han,Shelley M. Herbrich,Zhenlin Ju,Hoon Kim,Seth P. Lerner,Jun Li,Han Liang,Wen-Bin Liu,Philip L. Lorenzi,Yiling Lu,James M. Melott,Gordon B. Mills,Lam Nhat Nguyen,Xiaoping Su,Roeland Verhaak,Wenyi Wang,John N. Weinstein,Andrew Wong,Yang Yang,Jun Yao,Rong Yao,Kosuke Yoshihara,Yuan Yuan,Alfred K Yung,Nianxiang Zhang,Siyuan Zheng,Michael T. Ryan,David W. Kane,B. Arman Aksoy,Giovanni Ciriello,Gideon Dresdner,Jianjiong Gao,Benjamin Gross,Anders Jacobsen,André Kahles,Marc Ladanyi,William H. Lee,Kjong-Van Lehmann,Martin L. Miller,Ricardo Ramirez,Gunnar Rätsch,Boris Reva,Chris Sander,Nikolaus Schultz,Yasin Senbabaoglu,Ronglai Shen,Rileen Sinha,S. Onur Sumer,Yichao Sun,Barry S. Taylor,Nils Weinhold,Suzanne S. Fei,Paul T. Spellman,Christopher C. Benz,Daniel E. Carlin,Melisssa Cline,Brian Craft,Kyle Ellrott,Mary Goldman,David Haussler,Singer Ma,Sam Ng,Evan O. Paull,Amie Radenbaugh,Sofie R. Salama,Artem Sokolov,Joshua M. Stuart,Teresa Swatloski,Vladislav Uzunangelov,Peter Waltman,Christina Yau,Jing Zhu,Stanley R. Hamilton,Scott Abbott,Rachel Abbott,Nathan D. Dees,Kim D. Delehaunty,Li Ding,David J. Dooling,James M. Eldred,Catrina Fronick,Robert S. Fulton,Lucinda Fulton,Joelle Kalicki-Veizer,Krishna-Latha Kanchi,Cyriac Kandoth,Daniel C. Koboldt,David E. Larson,Timothy J. Ley,Ling Lin,Charles Lu,Vincent Magrini,Elaine R. Mardis,Michael D. McLellan,Joshua F. McMichael,Christopher A. Miller,Michelle O'Laughlin,Craig Pohl,Heather Schmidt,Scott M. Smith,Jason Walker,John W. Wallis,Michael C. Wendl,Richard K. Wilson,Todd Wylie,Qunyuan Zhang,Robert A. Burton,Mark A. Jensen,Ari B. Kahn,Todd Pihl,David Pot,Yunhu Wan,Douglas A. Levine,Aaron D. Black,Jay Bowen,Jessica Frick,Julie M. Gastier-Foster,Hollie A. Harper,Carmen Helsel,Kristen M. Leraas,Tara M. Lichtenberg,Cynthia McAllister,Nilsa C. Ramirez,Samantha Sharpe,Lisa Wise,Erik Zmuda,Stephen J. Chanock,Tanja Davidsen,John A. Demchok,Greg Eley,Ina Felau,Brad Ozenberger,Margi Sheth,Heidi J. Sofia,Louis M. Staudt,Roy Tarnuzzer,Zhining Wang,Liming Yang,Jiashan Zhang,Larsson Omberg,Adam A. Margolin,Benjamin J. Raphael,Fabio Vandin,Hsin-Ta Wu,Mark D.M. Leiserson,Stephen C. Benz,Charles J. Vaske,Houtan Noushmehr,Denise M. Wolf,Laura van 't Veer,Eric A. Collisson,Dimitris Anastassiou,Tai-Hsien Ou Yang,Nuria Lopez-Bigas,Abel Gonzalez-Perez,David Tamborero,Zheng Xia,Wei Li,Dong-Yeon Cho,Teresa M. Przytycka,Mark P. Hamilton,Sean E. McGuire,Sven Nelander,Patrik Johansson,Rebecka Jörnsten,Teresia Kling,Jose Miguel Sanchez,Kenna R. Mills Shaw +337 more
TL;DR: The Cancer Genome Atlas (TCGA) Research Network has profiled and analyzed large numbers of human tumors to discover molecular aberrations at the DNA, RNA, protein and epigenetic levels as mentioned in this paper.
Journal ArticleDOI
Extended-Connectivity Fingerprints
David Rogers,Mathew Hahn +1 more
TL;DR: A description of their implementation has not previously been presented in the literature, and ECFPs can be very rapidly calculated and can represent an essentially infinite number of different molecular features.
Journal ArticleDOI
A census of human cancer genes
P. Andrew Futreal,Lachlan J. M. Coin,Mhairi Marshall,Thomas A. Down,Tim Hubbard,Richard Wooster,Nazneen Rahman,Michael R. Stratton +7 more
TL;DR: A 'census' of cancer genes is conducted that indicates that mutations in more than 1% of genes contribute to human cancer.
Related Papers (5)
A link prediction approach to cancer drug sensitivity prediction.
Turki Turki,Turki Turki,Zhi Wei +2 more